Trinity Biotech (TRIB) Cost of Revenue (2016 - 2024)
Historic Cost of Revenue for Trinity Biotech (TRIB) over the last 16 years, with Q4 2024 value amounting to $11.0 million.
- Trinity Biotech's Cost of Revenue rose 2391.38% to $11.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $40.1 million, marking a year-over-year increase of 731.1%. This contributed to the annual value of $40.1 million for FY2024, which is 730.83% up from last year.
- Latest data reveals that Trinity Biotech reported Cost of Revenue of $11.0 million as of Q4 2024, which was up 2391.38% from $9.8 million recorded in Q3 2024.
- Trinity Biotech's Cost of Revenue's 5-year high stood at $17.1 million during Q4 2020, with a 5-year trough of $8.9 million in Q4 2023.
- Its 5-year average for Cost of Revenue is $11.6 million, with a median of $10.4 million in 2022.
- Its Cost of Revenue has fluctuated over the past 5 years, first soared by 6187.04% in 2021, then crashed by 3397.59% in 2022.
- Trinity Biotech's Cost of Revenue (Quarter) stood at $17.1 million in 2020, then dropped by 28.19% to $12.3 million in 2021, then dropped by 15.76% to $10.4 million in 2022, then dropped by 14.39% to $8.9 million in 2023, then grew by 23.91% to $11.0 million in 2024.
- Its last three reported values are $11.0 million in Q4 2024, $9.8 million for Q3 2024, and $10.1 million during Q2 2024.